# US 2022/0031823 A1 · Personalised immunogenic peptide identification platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031823 A1
- Document ID: US20220031823A1
- Status: Published application
- Kind: A1
- Application number: 17/448,020
- Filed: 2021-09-17
- Published: 2022-02-03
- Earliest claimed: 2017-03-03
- Assignees: Treos Bio Limited
- Applicants: Treos Bio Limited
- Inventors: Julianna Lisziewicz; Levente Molnár; Eniko R. Toke; József Toth; Orsolya Lorincz; Zsolt Csiszovszki; Eszter Somogyi; Katalin Pántya; Mónika Megyesi
- Web page: https://patentgrep.com/patent/US20220031823A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6869: Methods for sequencing
- G01N 33/505: {involving T-cells}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/575: for cancer
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55594: {from bacteria}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K 2039/6075: {Viral proteins}
- A61K 2039/70: {Multivalent vaccine}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing personalised pharmaceutical compositions comprising such polypeptide fragments, human subject-specific pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of the subject.

## Claims

### Claim 1

A human subject-specific pharmaceutical composition for treatment of a disease or disorder in a specific human subject, comprising
(a) at least two different polypeptides, each of the at least two different polypeptides being 10-50 amino acids in length and comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject, and wherein the T cell epitope of each of the at least two polypeptides are different from each other; and
(b) a pharmaceutically-acceptable adjuvant.

### Claim 2 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides.

### Claim 3 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, comprising 3-40 different polypeptides.

### Claim 4 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the T cell epitope that binds at least three HLA class I molecules of the subject comprises 7 to 11 amino acids, and/or the T cell epitope that binds at least three HLA class II molecules comprises 13 to 17 amino acids.

### Claim 5 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the epitopes of the at least two different polypeptides are from a single antigen.

### Claim 6 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the epitopes of the at least two different polypeptides are from two or more different antigens.

### Claim 7 (depends on 5)

The human subject-specific pharmaceutical composition of claim 5, wherein the antigen is an antigen expressed by a cancer cell, a neoantigen expressed by a cancer cell, a cancer-associated antigen, a tumor-associated antigen, or an antigen expressed by a target pathogenic organism, an antigen expressed by a virus, an antigen expressed by a bacterium, an antigen expressed by a fungus, an antigen associated with an autoimmune disorder, or is an allergen.

### Claim 8 (depends on 7)

The human subject-specific pharmaceutical composition of claim 7, wherein the cancer cell is from the subject.

### Claim 9 (depends on 5)

The human subject-specific pharmaceutical composition of claim 5, wherein the antigen is selected from the antigens listed in Tables 2 to 7.

### Claim 10 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the at least two different polypeptides further comprise up to 10 amino acids flanking the T cell epitope that are part of a consecutive sequence flanking the epitope in a corresponding antigen.

### Claim 11 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the at least two different polypeptides further comprise up to 10 amino acids flanking the T cell epitope that are not part of a consecutive sequence flanking the epitope in a corresponding antigen.

### Claim 12 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein two of the at least two polypeptides are arranged end to end or overlapping in a joined polypeptide.

### Claim 13 (depends on 12)

The human subject-specific pharmaceutical composition of claim 12, comprising two or more different joined polypeptides, wherein the two or more different joined polypeptides comprise different epitopes from each other.

### Claim 14 (depends on 13)

The human subject-specific pharmaceutical composition of claim 13, wherein the joined polypeptides have been screened to eliminate substantially all neoepitopes that span a junction between the two polypeptides and that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells of the subject;
(ii) is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; or
(iii) meets both requirements (i) and (ii).

### Claim 15 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the at least two polypeptides do not comprise any amino acid sequences that
(i) correspond to a fragment of a human polypeptide expressed in healthy cells; or
(ii) correspond to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

### Claim 16 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable diluent, carrier, preservative, or combination thereof.

### Claim 17 (depends on 1)

The human subject-specific pharmaceutical composition of claim 1, wherein the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

### Claim 18

A kit comprising, one or more separate containers each container comprising:
(i) one or more polypeptides being 10-50 amino acids in length comprising an amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject; and
(ii) a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof.

### Claim 19 (depends on 18)

The kit of claim 18, comprising at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides, wherein the amino acid sequence of the T cell epitope of each of the different polypeptides are different from each other.

### Claim 20 (depends on 18)

The kit of claim 18, further comprising a package insert.

### Claim 21

A human subject-specific pharmaceutical composition comprising:
a nucleic acid molecule expressing two or more polypeptides, each polypeptide being 10-50 amino acids in length comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject, wherein each of the two or more polypeptides comprises a different T cell epitope, wherein the polypeptides do not comprise amino acid sequences that are adjacent to each other in a corresponding antigen.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the nucleic acid molecule expresses at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides, each being 10-50 amino acids in length comprising an amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject, wherein the amino acid sequence of the T cell epitope of each of the different polypeptides are different from each other.

### Claim 23

A human subject-specific pharmaceutical composition for treatment of a disease or disorder in a specific human subject, comprising at least one different polypeptides, each of the at least one different polypeptides comprising at least a first region and a second region,
(i) the first region of 10-50 amino acids in length comprising an amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject,
(ii) the second region of 10-50 amino acids in length comprising an amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least two HLA class II molecules of the subject,
wherein the amino acid sequence of the T cell epitope of each of the first and second regions of each of the at least three different polypeptides comprise different sequences.

### Claim 24 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, comprising at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides.

### Claim 25 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, comprising 2-40 different polypeptides.

### Claim 26 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, wherein the T cell epitope that binds at least three HLA class I molecules of the subject comprises 7 to 11 amino acids, and/or the T cell epitope that binds at least three HLA class II molecules comprises 13 to 17 amino acids.

### Claim 27 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, wherein the epitopes of the first and second regions are from a single antigen.

### Claim 28 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, wherein the epitopes of the first and second regions are from two or more different antigens.

### Claim 29 (depends on 27)

The human subject-specific pharmaceutical composition of claim 27, wherein the antigen is an antigen expressed by a cancer cell, a neoantigen expressed by a cancer cell, a cancer-associated antigen, a tumor-associated antigen, or an antigen expressed by a target pathogenic organism, an antigen expressed by a virus, an antigen expressed by a bacterium, an antigen expressed by a fungus, an antigen associated with an autoimmune disorder, or is an allergen.

### Claim 30 (depends on 29)

The human subject-specific pharmaceutical composition of claim 29, wherein the cancer cell is from the subject.

### Claim 31 (depends on 27)

The human subject-specific pharmaceutical composition of claim 27, wherein the antigen is selected from the antigens listed in Tables 2 to 7.

### Claim 32 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, wherein the polypeptides have been screened to eliminate substantially all neoepitopes that span a junction between the two regions and that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells of the subject;
(ii) is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; or
(iii) meets both requirements (i) and (ii).

### Claim 33 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, wherein the at least one polypeptides do not comprise any amino acid sequences that
(i) correspond to a fragment of a human polypeptide expressed in healthy cells; or
(ii) correspond to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

### Claim 34 (depends on 23)

The human subject-specific pharmaceutical composition of claim 23, further comprising a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof.

### Claim 35 (depends on 34)

The human subject-specific pharmaceutical composition of claim 34, wherein the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

### Claim 36

A method of preparing a human subject-specific pharmaceutical composition for use in a method of treatment of a specific human subject, the method comprising:
(j) selecting a fragment of a polypeptide, which fragment has been identified as immunogenic for the subject by
a) determining whether the fragment comprises:
1) an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class I molecules of the subject; or
2) an amino acid sequence that is a T cell epitope capable of binding to at least three HLA class II molecules of the subject; or
3) or meets both requirements (1) and (2); and
b) identifying the sequence as a fragment of the polypeptide that is immunogenic for the subject;
(ii) selecting a first sequence of up to 50 consecutive amino acids of the polypeptide, which consecutive amino acids comprise the amino acid sequence of the fragment selected in step (i); and
(iii) preparing a subject-specific pharmaceutical composition having as active ingredients one or more polypeptides that together have all of the amino acid sequences selected in the preceding steps.

### Claim 37 (depends on 36)

The method of claim 36, further comprising prior to the preparing step repeating steps (i) to (ii) to select a second amino acid sequence of up to 50 consecutive amino acids of the same or a different polypeptide to the first amino acid sequence.

### Claim 38 (depends on 37)

The method of claim 37, further comprising, further repeating prior to the preparing step, steps (i) to (ii) one or more times to select one or more additional amino acid sequences of up to 50 consecutive amino acids of the same or different polypeptides to the first and second amino acid sequences.

### Claim 39 (depends on 36)

The method of claim 36, further comprising prior to the preparing step selecting a longer fragment of the polypeptide if the fragment selected in step (i) is an HLA class I-binding epitope, which longer fragment comprises the fragment selected in step (i); and is a T cell epitope capable of binding at least three HLA class II molecules of the subject.

### Claim 40 (depends on 36)

The method of claim 36, wherein each polypeptide either consists of one of the selected amino acid sequences, or comprises or consists of two or more of the selected amino acid sequences arranged end to end or overlapping in a single joined polypeptide.

### Claim 41 (depends on 36)

The method of claim 36, wherein any neoepitopes formed at the junction between any two of the selected amino acid sequences arranged end to end in a single joined polypeptide have been screened to eliminate substantially all polypeptides comprising a neoepitope amino acid sequence that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells;
(ii) is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; or
(iii) meets both requirements (i) and (ii).

### Claim 42 (depends on 36)

The method of claim 36, wherein the one or more polypeptides have been screened to eliminate polypeptides comprising an amino acid sequence that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells; or
(ii) corresponds to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

### Claim 43 (depends on 36)

The method of claim 36, further comprising determining HLA class I genotype and HLA class II genotype from a biological sample of the subject prior to step (i).

### Claim 44 (depends on 43)

The method of claim 43, wherein the determining HLA class I genotype and HLA class II genotype is performed by sequence based typing (SBT) methods.

### Claim 45 (depends on 43)

The method of claim 43, wherein the determining HLA class I genotype and HLA class II genotype is performed by sequencing, next generation sequencing, sequence specific primer (SSP) methods, or sequence specific oligonucleotide (SSO) methods.

### Claim 46 (depends on 43)

The method of claim 43, wherein the biological sample is blood, serum, plasma, saliva, buccal swab, urine, expiration, cell, or tissue.

### Claim 47 (depends on 43)

The method of claim 43, wherein the biological sample is saliva or a buccal swab.

### Claim 48

A method of treating a cancer in a specific human subject in need thereof comprising,
administering to a specific human subject a pharmaceutical composition comprising at least one polypeptide,
each of the at least one polypeptide being 10-50 amino acids in length comprising a first amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject,
wherein the T cell epitope of each of the at least one polypeptide is from an antigen that is specific for the cancer.

### Claim 49 (depends on 48)

The method of claim 48, wherein the composition comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides, wherein the amino acid sequence of the T cell epitope of each of the different polypeptides are different from each other, and are from one or more antigens that are expressed by a cancer cell from the subject.

### Claim 50 (depends on 48)

The method of claim 48, wherein the composition comprises 2-40 different polypeptides.

### Claim 51 (depends on 48)

The method of claim 48, wherein T cell epitope that binds at least three HLA class I molecules of the subject comprises 7 to 11 amino acids, and/or the T cell epitope that binds at least three HLA class II molecules comprises 13 to 17 amino acids.

### Claim 52 (depends on 48)

The method of claim 48, wherein the composition comprises at least two different polypeptides and the epitopes of the amino acid sequences of the at least two different polypeptides are from a single antigen.

### Claim 53 (depends on 48)

The method of claim 48, wherein the composition comprises at least two different polypeptides and the epitopes of the at least two different polypeptides are from two or more different antigens.

### Claim 54 (depends on 48)

The method of claim 48, wherein the one or more antigen is a neoantigen expressed by a cancer cell, a cancer-associated antigen, or a tumor-associated antigen.

### Claim 55 (depends on 48)

The method of claim 48, wherein the one or more antigen is selected from the antigens listed in Table 2.

### Claim 56 (depends on 48)

The method of claim 48, wherein the at least one different polypeptides further comprise up to 10 amino acids flanking the T cell epitope that are part of a consecutive sequence flanking the epitope in a corresponding antigen.

### Claim 57 (depends on 48)

The method of claim 48, wherein the at least one different polypeptides further comprise up to 10 amino acids flanking the T cell epitope that are not part of a consecutive sequence flanking the epitope in a corresponding antigen.

### Claim 58 (depends on 48)

The method of claim 48, wherein the composition comprises at least two different polypeptides and two of the polypeptides are arranged end to end or overlapping in a joined polypeptide.

### Claim 59 (depends on 58)

The method of claim 58, comprising two or more different joined polypeptides, wherein the two or more different joined polypeptides comprise different epitopes from each other.

### Claim 60 (depends on 59)

The method of claim 59, wherein the joined polypeptides have been screened to eliminate substantially all neoepitopes that span a junction between the two polypeptides and that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells of the subject;
(ii) is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; or
(iii) meets both requirements (i) and (ii).

### Claim 61 (depends on 48)

The method of claim 48, wherein the at least one polypeptide does not comprise any amino acid sequences that
(i) correspond to a fragment of a human polypeptide expressed in healthy cells; or
(ii) correspond to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

### Claim 62 (depends on 48)

The method of claim 48, wherein the composition further comprises a pharmaceutically acceptable adjuvant, diluent, carrier, preservative, or combination thereof.

### Claim 63 (depends on 62)

The method of claim 62, wherein the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

### Claim 64 (depends on 48)

The method of claim 48, further comprising administering a chemotherapeutic agent, a targeted therapy, radiation therapy, a checkpoint inhibitor, another immunotherapy, or combination thereof.

### Claim 65

A human subject-specific pharmaceutical composition for treatment of a disease or disorder in a specific human subject, comprising (a) a polypeptide of 10-50 amino acids in length and comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject; and (b) a pharmaceutically-acceptable adjuvant.

### Claim 66 (depends on 65)

The human subject-specific pharmaceutical composition of claim 65, comprising at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, or at least 12 different polypeptides, each of the different polypeptides being 10-50 amino acids in length comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject, wherein the amino acid sequence of the T cell epitope of each of the different polypeptides are different from each other.

### Claim 67 (depends on 66)

The human subject-specific pharmaceutical composition of claim 66, comprising 2-40 different polypeptides.

### Claim 68 (depends on 65)

The human subject-specific pharmaceutical composition of claim 65, wherein the T cell epitope that binds at least three HLA class I molecules of the subject comprises 7 to 11 amino acids, and/or the T cell epitope that binds at least three HLA class II molecules comprises 13 to 17 amino acids.

### Claim 69 (depends on 66)

The human subject-specific pharmaceutical composition of claim 66, comprising at least two different polypeptides, wherein the epitopes of the at least two different polypeptides are from a single antigen.

### Claim 70 (depends on 66)

The human subject-specific pharmaceutical composition of claim 66, comprising at least two different polypeptides, wherein the epitopes of the at least two different polypeptides are from two or more different antigens.

### Claim 71 (depends on 69)

The human subject-specific pharmaceutical composition of claim 69, wherein the antigen is an antigen expressed by a cancer cell, a neoantigen expressed by a cancer cell, a cancer-associated antigen, a tumor-associated antigen, or an antigen expressed by a target pathogenic organism, an antigen expressed by a virus, an antigen expressed by a bacterium, an antigen expressed by a fungus, an antigen associated with an autoimmune disorder, or is an allergen.

### Claim 72 (depends on 71)

The human subject-specific pharmaceutical composition of claim 71, wherein the cancer cell is from the subject.

### Claim 73 (depends on 69)

The human subject-specific pharmaceutical composition of claim 69, wherein the antigen is selected from the antigens listed in Tables 2 to 7.

### Claim 74 (depends on 69)

The human subject-specific pharmaceutical composition of claim 69, comprising at least two different polypeptides, wherein two of the polypeptides are arranged end to end or overlapping in a joined polypeptide.

### Claim 75 (depends on 65)

The human subject-specific pharmaceutical composition of claim 65, wherein the adjuvant is selected from the group consisting of Montanide ISA-51, QS-21, GM-CSF, cyclophosamide, bacillus Calmette-Guerin (BCG), corynbacterium parvum, levamisole, azimezone, isoprinisone, dinitrochlorobenezene (DNCB), keyhole limpet hemocyanins (KLH), Freunds adjuvant (complete), Freunds adjuvant (incomplete), mineral gels, aluminum hydroxide (Alum), lysolecithin, pluronic polyols, polyanions, oil emulsions, dinitrophenol, diphtheria toxin (DT), and combinations thereof.

### Claim 76 (depends on 65)

The human subject-specific pharmaceutical composition of claim 65, comprising at least two different polypeptides, wherein two of the at least two polypeptides are arranged end to end or overlapping in a joined polypeptide.

### Claim 77 (depends on 76)

The human subject-specific pharmaceutical composition of claim 76, comprising two or more different joined polypeptides, wherein the two or more different joined polypeptides comprise different epitopes from each other.

### Claim 78 (depends on 77)

The human subject-specific pharmaceutical composition of claim 77, wherein the joined polypeptides have been screened to eliminate substantially all neoepitopes that span a junction between the two polypeptides and that
(i) corresponds to a fragment of a human polypeptide expressed in healthy cells of the subject;
(ii) is a T cell epitope capable of binding to at least two HLA class I molecules of the subject; or
(iii) meets both requirements (i) and (ii).

### Claim 79 (depends on 66)

The human subject-specific pharmaceutical composition of claim 66, wherein the at least two polypeptides do not comprise any amino acid sequences that
(i) correspond to a fragment of a human polypeptide expressed in healthy cells; or
(ii) correspond to a fragment of a human polypeptide expressed in healthy cells and is a T cell epitope capable of binding to at least two HLA class I molecules of the subject.

### Claim 80

A kit comprising:
(a) a first human subject-specific pharmaceutical composition comprising (i) a first polypeptide of 10-50 amino acids in length and comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject; and (ii) a pharmaceutically-acceptable adjuvant;
(b) a second human subject-specific pharmaceutical composition comprising (i) a second polypeptide of 10-50 amino acids in length and comprising a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject; and (ii) a pharmaceutically-acceptable adjuvant,
wherein the first and second polypeptides comprise different T cell epitopes.

### Claim 81 (depends on 80)

The kit of claim 80, wherein the first composition and/or the second composition comprise one or more additional polypeptides, wherein each additional polypeptide being of 10-50 amino acids in length comprising an amino acid sequence that is a T cell epitope that binds at least three HLA class I molecules of the subject and/or at least three HLA class II molecules of the subject, wherein the amino acid sequences comprise different T cell epitopes.
